HDAC9 and neoplasm: Combining HDAC inhibitors with other anti-tumor agents, including microtubule-targeting agents (MTAs), appears to be a rational strategy to improve the effectiveness of single-target drugs for cancer treatment due to their synergistic effect on cellular processes in cancer cells [28].